Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 4, 2004, Pages 1220-1232

  Bischof, Marc ^a   Abdollahi, Amir ^a,b   Gong, Ping ^a   Stoffregen, Clemens ^c   Lipson, Kenneth E ^d   Debus, Jürgen ^a   Weber, Klaus J ^a   Huber, Peter E ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ELI LILLY AND COMPANY   (United States)

^d SUGEN INC   (United States)

Author keywords

Alimta; Antiangiogenesis; Chemotherapy; Irradiation; Pemetrexed; SU5416; Triple combination

Indexed keywords

ANTIANGIOGENESIS; ANTICANCER; CLONOGENIC ASSAYS; PROSTRATE CANCER CELLS (PC3);

CHEMOTHERAPY; DNA; ENZYME INHIBITION; IRRADIATION; SIGNALING; TOXICITY; TUMORS;

CELLS;

CASPASE 3; MATRIGEL; PEMETREXED; PROTEIN KINASE B; SEMAXANIB; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CHEMOTHERAPY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; ENDOTHELIUM CELL; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION; SURVIVAL; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; ENDOTHELIAL CELLS; GLUTAMATES; GUANINE; HUMANS; INDOLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; PYRROLES; TUMOR STEM CELL ASSAY;

EID: 7444245046     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.07.689     Document Type: Article

References (39)

1. A. Forastiere, W. Koch, A. Trotti Head and neck cancer N Engl J Med 345 2001 1890 1900
2. D.P. Ryan, C.C. Compton, R.J. Mayer Carcinoma of the anal canal N Engl J Med 342 2000 792 800
3. P.M. Harari, S.M. Huang Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation Int J Radiat Oncol Biol Phys 49 2001 427 433
4. D.J. Buchsbaum, J.A. Bonner, W.E. Grizzle Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine and radiation Int J Radiat Oncol Biol Phys 54 2002 1180 1193
5. J. Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182 1186
6. J. Folkman How is blood vessel growth regulated in normal and neoplastic tissue? Adv Cancer Res 46 1985 467 473
7. N. Weidner, J.P. Semple, W.R. Welch Tumor angiogenesis correlates with metastasis in invasive breast carcinoma New Engl J Med 1 1991 324 329
8. M. Valter, A. Hugel, S. Huang Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis Cancer Res 59 1999 3374 3378
9. S. Cheng, H.J. Huang, M. Nagane Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor Proc Natl Acad Sci 16 1996 8502 8507
10. D. Gorski, M. Beckett, N. Jaskowiak Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
11. A. Abdollahi, K.E. Lipson, X. Han SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro Cancer Res 63 2003 3755 3763
12. L. Geng, E. Donnelly, G. McMahon Inhibition of vascular endothelial growth factor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
13. S.V. Kozin, Y. Boucher, D.J. Hicklin Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res 61 2001 39 44
14. Y. Kakeji, B.A. Teicher Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents Invest New Drugs 15 1997 39 48
15. R.S. Kerbel Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results J Clin Oncol 19 2001 45
16. B.A. Teicher, S.A. Holden, A. Gulshan Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents Int J Cancer 57 1994 920 927
17. A.T. Fong, L.K. Shawver, L. Sun SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res 59 1999 99 9106
18. D.B. Mendel, A.D. Laird, B.D. Smolich Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent Anti Cancer Drug Design 15 2000 29 41
19. A.R. Hanauske, V. Chen, P. Paoletti Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors Oncologist 6 2001 363 373
20. V.J. Chen, J.R. Bewley, S.L. Andis Cellular pharmacology of MTA: A correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells Semin Oncol 26 1999 48 54
21. M. Bischof, K.J. Weber, J. Blatter Interaction of Pemetrexed disodium (Alimta, multi targeted antifolate) and irradiation in vitro Int J Radiat Oncol Biol Phys 52 2002 1381 1388
22. M. Bischof, P.E. Huber, M. Wannenmacher Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases Int J Radiat Oncol Biol Phys 57 2003 289 292
23. B.A. Teicher, V. Chen, C. Shih Treatment regimens including the Multitargeted antifolate LY231514 in human tumor xenografts Clin Cancer Res 6 2000 1016 1023
24. E. Edwards, L. Geng, J. Tan Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation Cancer Res 62 2002 4671 4677
25. J. Schfer, J. Bachtler, A. Engling Suppression of apoptosis and clonogenic survival in irradiated human lymphoblasts with different TP53 status Radiat Res 158 2002 699 706
26. L.H. Hartwell, T.A. Weinert Checkpoints: Controls that ensure the order of cell cycle events Science 246 1989 629 634
27. G. Klement, S. Baruchel, J. Rak Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 2000 15 24
28. M. Garcia-Barros, F. Paris, C. Cordon-Cardo Tumor response to radiotherapy regulated by endothelial cell apoptosis Science 300 2003 1155 1159
29. J.H. Hendry, C.M. West Apoptosis and mitotic cell death: Their relative contributions to normal-tissue and tumour radiation response Int J Radiat Biol 71 1997 709 719
30. Y. Basaki, K. Aoyagi, L. Chikahisa UFT and its metabolites inhibit cancer induced angiogenesis via a VEGF-related pathway Oncology 14 2000 68 71
31. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003:3646.
32. A. Abdollahi, P. Hahnfeldt, C. Maercker Endostatin's antiangiogenic signaling network Mol Cell 13 2004 649 663
33. R. Masood, A. Kundra, T.S. Zhu Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops Int J Cancer 104 2003 603 610
34. J.S. Park, L. Qiao, Z.Z. Su Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activate protein kinase dependent pathways Oncogene 20 2001 3266 3280
35. H. Uehara, S.J. Kim, T. Karashima Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases J Natl Cancer Inst 95 2003 458 470
36. T. Kilic, J.A. Alberta, P.R. Zdunek Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class Cancer Res 60 2000 5143 5150
37. J. Folkman, P. Hahnfeldt, L. Hlatky Cancer: Looking outside the genome Nat Rev Mol Cell Biol 1 2000 76 79
38. R.S. Kerbel Inhibition of tumor angiogenesis as a strategy to circumvent resistance to anti-cancer therapeutic agents Bio Essays 1 1991 31
39. A. Abdollahi, K.E. Lipson, A. Sckell Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects Cancer Res 63 2003 8890 8898